JP2024522949A5 - - Google Patents

Info

Publication number
JP2024522949A5
JP2024522949A5 JP2023563256A JP2023563256A JP2024522949A5 JP 2024522949 A5 JP2024522949 A5 JP 2024522949A5 JP 2023563256 A JP2023563256 A JP 2023563256A JP 2023563256 A JP2023563256 A JP 2023563256A JP 2024522949 A5 JP2024522949 A5 JP 2024522949A5
Authority
JP
Japan
Prior art keywords
chimeric protein
protein complex
cells
modified
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522949A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/025143 external-priority patent/WO2022221746A1/en
Publication of JP2024522949A publication Critical patent/JP2024522949A/ja
Publication of JP2024522949A5 publication Critical patent/JP2024522949A5/ja
Pending legal-status Critical Current

Links

JP2023563256A 2021-04-16 2022-04-16 Il-2系構築物 Pending JP2024522949A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163175827P 2021-04-16 2021-04-16
US63/175,827 2021-04-16
US202263297330P 2022-01-07 2022-01-07
US63/297,330 2022-01-07
PCT/US2022/025143 WO2022221746A1 (en) 2021-04-16 2022-04-16 Il-2 based constructs

Publications (2)

Publication Number Publication Date
JP2024522949A JP2024522949A (ja) 2024-06-24
JP2024522949A5 true JP2024522949A5 (cg-RX-API-DMAC7.html) 2025-04-23

Family

ID=83639788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563256A Pending JP2024522949A (ja) 2021-04-16 2022-04-16 Il-2系構築物

Country Status (9)

Country Link
US (1) US20240199714A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323392A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024522949A (cg-RX-API-DMAC7.html)
KR (1) KR20240021155A (cg-RX-API-DMAC7.html)
AU (1) AU2022258840A1 (cg-RX-API-DMAC7.html)
CA (1) CA3215204A1 (cg-RX-API-DMAC7.html)
IL (1) IL307574A (cg-RX-API-DMAC7.html)
MX (1) MX2023012131A (cg-RX-API-DMAC7.html)
WO (1) WO2022221746A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2024118878A2 (en) * 2022-11-30 2024-06-06 The Regents Of The University Of California Multispecific engineered biomolecules and uses thereof
WO2024119193A2 (en) * 2022-12-02 2024-06-06 AskGene Pharma, Inc. Mutant il-2 polypeptides and il-2 prodrugs
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2026015864A1 (en) * 2024-07-12 2026-01-15 Outpace Bio, Inc. Cd8 binding polypeptides and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
JP6640834B2 (ja) * 2014-08-11 2020-02-05 デリニア, インコーポレイテッド 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
IL304950A (en) * 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
EP3538548A4 (en) * 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
AU2018273914A1 (en) * 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
KR102777151B1 (ko) * 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
KR20260100427A (ko) * 2018-03-28 2026-06-29 오리오니스 바이오사이언시즈 인코포레이티드 이작용성 단백질 및 이의 작제물
PE20210313A1 (es) * 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
AU2019288496B2 (en) * 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof
JP7778571B2 (ja) * 2019-06-05 2025-12-02 アッシャー バイオセラピューティクス, インコーポレイテッド 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
TWI815194B (zh) * 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法

Similar Documents

Publication Publication Date Title
Jin et al. Emerging new therapeutic antibody derivatives for cancer treatment
Tapia-Galisteo et al. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
JP2022534837A5 (cg-RX-API-DMAC7.html)
US11357826B2 (en) IL-10 EGFR antibody fusion protein and uses thereof
Strohl Current progress in innovative engineered antibodies
RU2018139339A (ru) Новые биспецифические полипептиды против cd137
JP2019523630A5 (cg-RX-API-DMAC7.html)
JP2021531754A5 (cg-RX-API-DMAC7.html)
JP2020506727A5 (cg-RX-API-DMAC7.html)
JP2020530298A5 (cg-RX-API-DMAC7.html)
CN105431205B (zh) 抑制肿瘤转移的IgE抗体
US20230235011A1 (en) Fc-cd80 fusion protein and conjugates thereof and their uses
Ahmed et al. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody
JP2023546725A5 (cg-RX-API-DMAC7.html)
JP2022512891A5 (cg-RX-API-DMAC7.html)
CN112930357A (zh) B7-h7结合剂及其使用方法
JP2023536086A (ja) Pd‐1×ctla‐4二重特異性分子の使用のための方法
JP2022550345A5 (cg-RX-API-DMAC7.html)
US12215164B2 (en) Immunotoxins with albumin binding domain
WO2024078479A1 (zh) 一种异源二聚体融合蛋白及其应用
TW202430553A (zh) Psma抗體及其用途
Zhu et al. Highlights of antibody engineering and therapeutics 2019 in San Diego, USA: bispecific antibody design and clinical applications
CN115246885B (zh) 一种双特异性抗体及其应用
IL322796A (en) Anti-cntn4 antibody and its use
AU2023269782A1 (en) Engineered interleukin-2 receptor beta reduced-binding agonist